Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023 Feb 1;72(2):338–44.

Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology. 2021.

Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes & Development. 2021 Jun 1;35(11–12):787–820.

Huang JL, Oshi M, Endo I, Takabe K. Clinical relevance of stem cell surface markers CD133, CD24, and CD44 in colorectal cancer. American Journal of Cancer Research. 2021 Oct 15;11(10):5141.

Soleimani A, Saeedi N, Al-Asady AM, Nazari E, Hanaie R, Khazaei M, Ghorbani E, Akbarzade H, Ryzhikov M, Avan A, Mehr SM. Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights. Current Pharmaceutical Design. 2024 May 1;30(18):1386–97.

Ehteram H, Aslanbeigi F, Ghoochani Khorasani E, Tolouee M, Haddad Kashani H. Expression and prognostic significance of stem cell marker CD133 in survival rate of patients with colon cancer. Oncology and Therapy. 2022 Dec;10(2):451–61.

Yang J, Aljitawi O, Van Veldhuizen P. Prostate cancer stem cells: the role of CD133. Cancers. 2022.

You CZ, Xu H, Zhao FS, Dou J. A Validation Study of CD133 as a Reliable Marker for Identification of Colorectal Cancer Stem-Like Cells. Bulletin of Experimental Biology and Medicine. 2024 Jan;176(3):369–75.

Korn P, Kampmann A, Spalthoff S, Jehn P, Tavassol F, Lentge F, Gellrich NC, Zimmerer R. Suitability of CD133 as a marker for cancer stem cells in melanoma. Asian Pacific Journal of Cancer Prevention: APJCP. 2021 May;22(5):1591.

Ziranu P, Aimola V, Pretta A, Dubois M, Murru R, Liscia N, Cau F, Persano M, Deias G, Palmas E, Loi F. New horizons in metastatic colorectal cancer: prognostic role of CD44 expression. Cancers. 2023 Feb 14;15(4):1212.

Liu B, Liu T, Liu Y, Feng X, Jiang X, Long J, Ye S, Chen D, Wang J, Yang Z. TSG-6 promotes cancer cell aggressiveness in a CD44-dependent manner and reprograms normal fibroblasts to create a pro-metastatic microenvironment in colorectal cancer. International Journal of Biological Sciences. 2022 Feb 7;18(4):1677.

Ziranu P, Pretta A, Aimola V, Cau F, Mariani S, D’Agata AP, Codipietro C, Rizzo D, Dell’Utri V, Sanna G, Moledda G. CD44: a new prognostic marker in colorectal cancer?. Cancers. 2024 Apr 19;16(8):1569.

Tunuguntla A, Suresh TN. Association between the immunohistochemistry expression of E-cadherin, beta-catenin, and CD44 in colorectal adenocarcinoma. Cureus. 2023.

Nersisyan S, Ahlers AK, Lange T, Wicklein D, Galatenko A, Bohnenberger H, Elakad O, Conradi LC, Genduso S, Maar H, Schiecke A. Low expression of CD24 is associated with poor survival in colorectal cancer. Biochimie. 2022 Jan 1;192:91–101.

Klimeck L, Heisser T, Hoffmeister M, Brenner H. Colorectal cancer: A health and economic problem. Best Practice & Research Clinical Gastroenterology. 2023 Oct 1;66:101839.

Alzahrani SM, Al Doghaither HA, Al-Ghafari AB. General insight into cancer: An overview of colorectal cancer. Molecular and Clinical Oncology. 2021 Dec;15(6):271.

Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World Journal of Gastrointestinal Surgery. 2021 Dec 27;13(12):1567.

Yildirim M, Cinar A. Classification with respect to colon adenocarcinoma and colon benign tissue of colon histopathological images with a new CNN model: MA_ColonNET. International Journal of Imaging Systems and Technology. 2022 Jan;32(1):155–62.

Walter RJ, Sonnentag SJ, Orian-Rousseau V, Munoz-Sagredo L. Plasticity in colorectal cancer: Why cancer cells differentiate. Cancers. 2021 Feb 22;13(4):918.

Erisik D, Ozdil B, Acikgoz E, Asker Abdikan CS, Yesin TK, Aktug H. Differences and similarities between colorectal cancer cells and colorectal cancer stem cells: molecular insights and implications. ACS Omega. 2023 Aug 9;8(33):30145–57.

Xia P, Liu DH, Xu ZJ, Ren F. Cancer stem cell markers for urinary carcinoma. Stem Cells International. 2022.

Shoutko AN, Karamullin MA. Physiological Variance of CD34 Marker’s Content in Twenty Tissues Determining Different Risks of Cardiovascular Diseases and Cancer in Them. Open Journal of Biophysics. 2024.

Gisina A, Kim Y, Yarygin K, Lupatov A. Can CD133 be regarded as a prognostic biomarker in oncology: pros and cons. International Journal of Molecular Sciences. 2023 Dec 12;24(24):17398.

Moreno-Londoño AP, Robles-Flores M. Functional roles of CD133: more than stemness associated factor regulated by the microenvironment. Stem Cell Reviews and Reports. 2024.

Wattanawongdon W, Bathpho TS, Tongtawee T. Co-expression of LGR5 and CD133 cancer stem cell predicts a poor prognosis in patients with gastric cancer. The Turkish Journal of Gastroenterology. 2021 Mar 1;32(3):261.

Kunihiro AG, Sarrett SM, Lastwika KJ, Solan JL, Pisarenko T, Keinänen O, Rodriguez C, Taverne LR, Fitzpatrick AL, Li CI, Houghton AM. CD133 as a biomarker for an autoantibody-to-immunoPET paradigm for the early detection of small cell lung cancer. Journal of Nuclear Medicine. 2022 Nov 1;63(11):1701–7.

Reuvekamp T, Janssen LL, Ngai LL, Carbaat-Ham J, den Hartog D, Scholten WJ, Kelder A, Hanekamp D, Wensink E, van Gils N, Gradowska P. The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B: Clinical Cytometry. 2025 Jan;108(1):23–34.

Sato T, Oshi M, Huang JL, Chida K, Roy AM, Endo I, Takabe K. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer. Breast Cancer Research and Treatment. 2024 Nov;208(2):415–27.

Pricope DL, Grigoraș A, Dimofte GM, Terinte C, Amalinei C. CD133 and CD166 Stem Cells Markers Expression, Clinicopathological Parameters, and Fragmentation Response Patterns of ypT3 Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Biomedicines. 2025 May 26;13(6):1300.

Hefni AM, Sayed AM, Hussien MT, Abdalla AZ, Gabr AG. CD133 is an independent predictive and prognostic marker in metastatic breast cancer. Cancer Biomarkers. 2022 May;35(2):207–15.

Sawai K, Koneri K, Kimura Y, Goi T. CD133 Expression in Circulating Tumor Cells as a Prognostic Marker in Colorectal Cancer. International Journal of Molecular Sciences. 2025 May 15;26(10):4740.

Jovanović L, Šošić-Jurjević B, Ćirković A, Dragičević S, Filipović B, Milenković S, Dugalić S, Gojnić-Dugalić M, Nikolić A. Diagnostic Potential of CD44, CD133, and VDR in Epithelial Ovarian Tumors: Association with Histopathology Parameters. International Journal of Molecular Sciences. 2025 Apr 15;26(8):3729.

Al-Kaabi M, Noel K, Al-Rubai AJ. Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium. Journal of Medicine and Life. 2022.

Ikram D, Masadah R, Nelwan BJ, Zainuddin AA, Ghaznawie M, Wahid S. CD133 act as an essential marker in ovarian carcinogenesis. Asian Pacific Journal of Cancer Prevention: APJCP. 2021 Nov;22(11):3525.

Chai X, Wu X, Ren J, Du K, Wu X, Feng F, Zheng J. Expression of HIF-1α, ANXA3, CD133 and their associations with clinicopathological parameters in human colon carcinoma. Translational Cancer Research. 2022 Jun;11(6):1644.

Jiang P, Tian C, Zheng Y, Gong C, Wang J, Liu Y. The prognostic value of co-expression of stemness markers CD44 and CD133 in endometrial cancer. Frontiers in Oncology. 2024 Apr 19;14:1338908.

Zhou H, Shen H, Xiang F, Yang X, Li R, Zeng Y, Liu Z. Correlation analysis of the expression of mesenchymal circulating tumor cells and CD133 with the prognosis of colorectal cancer. American Journal of Translational Research. 2023 May 15;15(5):3489.

Suman S, Hota SK, Misra P, Sahu N et al. Immunohistochemical expression of the stem cell marker CD133 in colorectal carcinoma. Cureus. 2023.

Rachmita PA, Hilbertina N, Yenita Y, Agus S, Suchitra A, Yetti H. Correlation of CD133 Expression with Tumor Location and Lymph Node Involvement in Colorectal Carcinoma. Majalah Patologi Indonesia. 2023 Oct 5;32(3).

Coelho D, Estêvão D, Oliveira MJ, Sarmento B. Radioresistance in rectal cancer: can nanoparticles turn the tide?. Molecular Cancer. 2025.

Gholamzad A, Khakpour N, Khosroshahi EM, Asadi S, Koohpar ZK, Matinahmadi A, Jebali A, Rashidi M, Hashemi M, Sadi FH, Gholamzad M. Cancer stem cells: The important role of CD markers, Signaling pathways, and MicroRNAs. Pathology-Research and Practice. 2024 Feb 28:155227.

Chen J, Wu S, Peng Y, Zhao Y, Dong Y, Ran F, Geng H, Zhang K, Li J, Huang S, Wang Z. Constructing a cancer stem cell related prognostic model for predicting immune landscape and drug sensitivity in colorectal cancer. Frontiers in Pharmacology. 2023 Jun 12;14:1200017.

Zou KL, Lan Z, Cui H, Zhao YY, Wang WM, Yu GT. CD24 blockade promotes anti-tumor immunity in oral squamous cell carcinoma. Oral Diseases. 2024 Mar;30(2):163–71.

Sihombing UH, Andrijono A, Purwoto G, Gandamihardja S, Harahap AR, Rustamadji P, Kekalih A, Widyawati R, Fuady DR. CD44+/CD24-Expression as predictors of ovarian cancer chemoresistance: Immunohistochemistry and flow cytometry study. Journal of the Egyptian National Cancer Institute. 2022 Oct 24;34(1):44.

Yaghjyan L, Heng YJ, Baker GM, Bret-Mounet V, Murthy D, Mahoney MB, Mu Y, Rosner B, Tamimi RM. Reliability of CD44, CD24, and ALDH1A1 immunohistochemical staining: Pathologist assessment compared to quantitative image analysis. Frontiers in Medicine. 2022 Dec 14;9:1040061.

Sajedifar M, Ashtiani AJ, Nadoushan MJ. Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study. Iranian Journal of Pathology. 2024 Jul 24;19(3):306.